Inform patients of the following:
- VARIZIG is intended to reduce the severity of chickenpox infections. Please see your doctor if you develop the signs and symptoms of varicella.
- VARIZIG is prepared from human plasma and therefore, may contain infectious agents such as viruses that can cause disease.
- The risk that products derived from human plasma will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses during manufacturing.
- Despite these measures, products derived from human plasma can still potentially transmit disease.
- There is also the possibility that unknown infectious agents may be present in such products.
Tell patients that persons known to have severe, potentially life-threatening reactions to human immune globulin products should not receive VARIZIG or any other immune globulin products unless the risk has been justified.
Tell patients that persons who are deficient in IgA may have the potential for developing anti-IgA antibodies and have severe potentially life threatening allergic reactions.
- In the case of allergic or anaphylactic reaction, administration should be stopped immediately.
- In the case of shock, the current medical standards for treatment of shock should be administered.
Inform patients that administration of immune globulin may interfere with the response to live virus vaccines (e.g. measles, mumps, rubella and varicella), and instruct them to notify their immunizing physician of recent therapy with VARIZIG.
Last reviewed on RxList: 12/20/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional VariZIG Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.